Closed-Loop Insulin Delivery

How it works

Benefits

Comparisons

Evidence quality

Highlighted claims

• A fully automated closed-loop insulin delivery system requires no meal announcements and tailors insulin delivery dynamically to reduce complication risk. — Assessing the efficacy, safety and utility of fully closed-loop insulin delivery compared to standard insulin therapy with a continuous glucose monitor in adults with type 2 diabetes (COYOTE study): a randomised parallel study protocol
• The CamAPS HX system operates fully automatically, removing the burden of bolus decision-making from the user. — Assessing the efficacy, safety and utility of fully closed-loop insulin delivery compared to standard insulin therapy with a continuous glucose monitor in adults with type 2 diabetes (COYOTE study): a randomised parallel study protocol
• The COYOTE study is designed to determine whether closed-loop benefits generalise to a larger and more diverse multinational population. — Assessing the efficacy, safety and utility of fully closed-loop insulin delivery compared to standard insulin therapy with a continuous glucose monitor in adults with type 2 diabetes (COYOTE study): a randomised parallel study protocol
• Because both arms use CGM, any observed benefit in the COYOTE study is attributable specifically to the closed-loop algorithm. — Assessing the efficacy, safety and utility of fully closed-loop insulin delivery compared to standard insulin therapy with a continuous glucose monitor in adults with type 2 diabetes (COYOTE study): a randomised parallel study protocol
• A prior single-centre pilot study of 26 adults demonstrated that fully closed-loop insulin therapy significantly improved HbA1c compared with standard therapy without increasing hypoglycaemia risk. — Assessing the efficacy, safety and utility of fully closed-loop insulin delivery compared to standard insulin therapy with a continuous glucose monitor in adults with type 2 diabetes (COYOTE study): a randomised parallel study protocol